Pemexen Injection 100 mg/4 ml contains Pemetrexed, a chemotherapy medication used for the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Pemetrexed is an antifolate antineoplastic agent that inhibits key enzymes involved in the synthesis of nucleotides, preventing cancer cells from replicating and dividing.

This sterile injection is intended for intravenous administration under strict medical supervision. Pemetrexed works by disrupting the folate-dependent metabolic pathways required for DNA and RNA synthesis in rapidly dividing tumor cells, thereby slowing tumor growth and promoting cancer cell death.

Pemexen Injection is commonly used as monotherapy or in combination with other chemotherapeutic agents, such as cisplatin, depending on the type and stage of cancer. Its formulation allows precise dosing and controlled administration in hospital settings, ensuring optimal therapeutic outcomes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Features

• Contains Pemetrexed 100 mg per 4 ml of sterile solution

• Antifolate chemotherapy for malignant pleural mesothelioma and NSCLC

• Intravenous injection for controlled hospital administration

• Inhibits nucleotide synthesis, preventing tumor cell replication

• Can be used alone or in combination with other chemotherapeutic agents

• Supports effective cancer management under oncologist supervision

Indications

Pemexen Injection 100 mg/4 ml is indicated for:

• Malignant pleural mesothelioma: As first-line treatment, often in combination with cisplatin

• Non-small cell lung cancer (NSCLC): As maintenance therapy or in advanced stages, depending on prior chemotherapy response

• Other off-label cancers: Only under strict oncologist supervision

Treatment requires individualized dosing and careful monitoring of patient response and side effects.

Mechanism of Action

Pemetrexed is a multi-targeted antifolate that inhibits enzymes crucial for nucleotide synthesis:

• Thymidylate synthase (TS): Reduces thymidine production for DNA synthesis

• Dihydrofolate reductase (DHFR): Prevents tetrahydrofolate regeneration

• Glycinamide ribonucleotide formyltransferase (GARFT): Inhibits purine nucleotide synthesis

By interfering with DNA and RNA synthesis, Pemetrexed selectively targets rapidly dividing cancer cells while minimizing effects on normal tissues.

Dosage and Administration

• Administered via intravenous infusion over 10 minutes or longer, as per oncologist instruction

• Dose is based on body surface area (mg/m²), typically 500 mg/m² every 21 days for NSCLC or mesothelioma

• Pre-medication with folic acid, vitamin B12, and corticosteroids is required to reduce hematologic and gastrointestinal toxicity

• Continuous monitoring of blood counts, liver and kidney function, and general health is essential

• Only to be used in hospital or clinical settings with trained oncology staff

Possible Side Effects

Common side effects include:

• Fatigue and weakness

• Nausea and vomiting

• Loss of appetite

• Hair thinning

• Low blood cell counts (anemia, neutropenia, thrombocytopenia)

• Mouth sores or mucositis

Serious side effects may include:

• Severe infections due to immunosuppression

• Liver or kidney function abnormalities

• Allergic reactions

• Gastrointestinal perforation (rare)

Patients must report any unusual symptoms promptly to their healthcare provider.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use only under oncologist supervision in a controlled clinical setting

• Monitor blood counts, liver and kidney function regularly

• Avoid live vaccines during treatment

• Inform your doctor of all medications to prevent interactions

• Not recommended during pregnancy or breastfeeding

Storage Instructions

• Store in a cool, dry place at 2–8°C

• Protect from light

• Keep in the original vial until use

• Keep out of reach of children.